Last update 03 Jul 2024
Vilzemetkib
Last update 03 Jul 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AL 2846, AL2846 |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Structure
Molecular FormulaC36H36F2N4O5 |
InChIKeyIXDALXNUFGTEMF-UHFFFAOYSA-N |
CAS Registry1363402-44-1 |
Related
17
Clinical Trials associated with VilzemetkibA Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsules Combined With TQB2450 Injection Compared With Docetaxel Injection in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed With Immunotherapy.
评价 AL2846 胶囊联合 TQB2450 注射液对比多西他赛注射液在经免疫治疗失败的晚期非小细胞肺癌患者中有效性和安全性的多中心、随机、双盲、平行对照 III 期临床试验。
[Translation] This is a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial to evaluate the efficacy and safety of AL2846 capsules combined with TQB2450 injection versus docetaxel injection in patients with advanced non-small cell lung cancer who have failed immunotherapy.
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsule in Iodine-resistant Differentiated Thyroid Cancer With Previous TKI Treatment Failure
100 Clinical Results associated with Vilzemetkib
Login to view more data
100 Translational Medicine associated with Vilzemetkib
Login to view more data
100 Patents (Medical) associated with Vilzemetkib
Login to view more data
100 Deals associated with Vilzemetkib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 05 Jun 2023 | |
| Differentiated Thyroid Gland Carcinoma | Phase 2 | CN | 24 Feb 2023 | |
| Ovarian Cancer | Phase 2 | CN | 15 Feb 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 03 Feb 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 03 Feb 2023 | |
| Neoplasms | Phase 2 | CN | 30 Jan 2022 | |
| Neurofibromatosis 1 | Phase 2 | CN | 07 Sep 2021 | |
| Neurofibrosarcoma | Phase 2 | CN | 07 Sep 2021 | |
| Bone metastases | Phase 2 | CN | 24 Sep 2020 | |
| Advanced Colorectal Adenocarcinoma | Phase 2 | CN | 20 Jul 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 15 | AL2846 + Gemcitabine | qerpowjdmq(qzbmdmttzn) = clzgvbfsxz hwuljrwgal (omwaawauah ) View more | - | 28 May 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free